Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

Seyyed Mortaza Haghgoo; Abdolamir Allameh; Esmaeil Mortaz; Johan Garssen; Gert Folkerts; Peter J Barnes; Ian M. Adcock

doi:10.1016/j.ejphar.2015.02.029

Related publications

Article2018

Treating ALK-positive non-small cell lung cancer

Dimitrios C. Ziogas, Anna Tsiara, Georgios Tsironis, Maria Lykka, Michalis Liontos, Aristotelis Bamias, Meletios A Dimopoulos

Letter2007

ERCC1-Specific Immunostaining in Non–Small-Cell Lung Cancer

Ken A. Olaussen, Pierre Fouret, Guido Guido Kroemer

Article2019

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Peng Liu, Liwei Zhao, Jonathan Pol, Sarah Lévesque, Adriana Petrazzuolo, Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Takahiro Yamazaki, Kristina Iribarren, Laura Senovilla, Lucillia Bezu, Erika Vacchelli, Valentina Sica, Andréa Melis, Tiffany Martin, Lin Xia, Heng Yang, Qingqing Li, Jinfeng Chen, Sylvère Durand, Fanny Aprahamian, Déborah Lefevre, Sophie Broutin, Angélo Paci, ,

Article2022

Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer

Pan Juncheng, Adrien Joseph, Antoine Lafarge, Isabelle Martins, Florine Obrist, Jonathan Pol, Ester Saavedra, Sijing Li, Allan Sauvat, Giulia Cerrato, Sarah Lévesque, Marion Leduc, Oliver Kepp, Sylvère Durand, Fanny Aprahamian, Nitharsshini Nirmalathansan, Judith Michels, Guido Guido Kroemer, Maria Castedo

Article2017

Gefitinib: an “orphan” drug for non-small cell lung cancer

Dimitrios C. Ziogas, Michalis Liontos, Anastasios Kyriazoglou, Georgios Tsironis, Aristotelis Bamias, Meletios A Dimopoulos